[Clinical experiences with femovan (Gynera)].

Abstract

The low dose oral contraceptive Femovan/Gynera which contains 0.03 mg Ethinylestradiol and 0.075 mg Gestoden was examined in several clinical trials. Those trials proved its contraceptive effectiveness, its controlling influence on the menstrual cycle and a low incidence of unwanted side-effects. The data reported are based on the experience of more than 100,000 women representing nearly 600,000 treatment cycles. The results of all the different investigations compiled here underline a high contraceptive effectiveness and excellent control of the cycle when using the respective preparation. The rate of unwanted side-effects was low.

• Authors: K Brill, B Düsterberg, M Albring
• Journal: Therapeutische Umschau. Revue therapeutique (Ther Umsch) Vol. 47 Issue 12 Pg. 958-65 (Dec 1990) ISSN: 0040-5930 [Print] Switzerland
• Vernacular Title: Klinische Erfahrungen mit Femovan (Gynera).
• PMID: 2096480 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Contraceptives, Oral, Combined
• Norpregnenes
• Femovan
• Ethinyl Estradiol

Topics

• Adolescent
• Adult
• Blood Pressure (drug effects)
• Body Weight (drug effects)
• Contraceptives, Oral, Combined (administration & dosage, adverse effects)
• Ethinyl Estradiol (administration & dosage, adverse effects)
• Female
• Humans
• Menstrual Cycle (drug effects)
• Norpregnenes (administration & dosage, adverse effects)
• Thromboembolism (chemically induced)